-
Rijksmuseum puts the spotlight on Roman poet's epic
-
Trump fuels EU push to cut cord with US tech
-
Fearless talent: Five young players to watch at the T20 World Cup
-
India favourites as T20 World Cup to begin after chaotic build-up
-
Voter swings raise midterm alarm bells for Trump's Republicans
-
Australia dodges call for arrest of visiting Israel president
-
Countries using internet blackouts to boost censorship: Proton
-
Top US news anchor pleads with kidnappers for mom's life
-
Thailand's pilot PM on course to keep top job
-
The coming end of ISS, symbol of an era of global cooperation
-
New crew set to launch for ISS after medical evacuation
-
Family affair: Thailand waning dynasty still election kingmaker
-
Japan's first woman PM tipped for thumping election win
-
Stocks in retreat as traders reconsider tech investment
-
LA officials call for Olympic chief to resign over Epstein file emails
-
Ukraine, Russia, US to start second day of war talks
-
Fiji football legend returns home to captain first pro club
-
Trump attacks US electoral system with call to 'nationalize' voting
-
Barry Manilow cancels Las Vegas shows but 'doing great' post-surgery
-
US households become increasingly strained in diverging economy
-
Four dead men: the cold case that engulfed a Colombian cycling star
-
Super Bowl stars stake claims for Olympic flag football
-
On a roll, Brazilian cinema seizes its moment
-
Rising euro, falling inflation in focus at ECB meeting
-
AI to track icebergs adrift at sea in boon for science
-
Indigenous Brazilians protest Amazon river dredging for grain exports
-
Google's annual revenue tops $400 bn for first time, AI investments rise
-
Last US-Russia nuclear treaty ends in 'grave moment' for world
-
Man City brush aside Newcastle to reach League Cup final
-
Guardiola wants permission for Guehi to play in League Cup final
-
Boxer Khelif reveals 'hormone treatments' before Paris Olympics
-
'Bad Boy,' 'Little Pablo' and Mordisco: the men on a US-Colombia hitlist
-
BHP damages trial over Brazil mine disaster to open in 2027
-
Dallas deals Davis to Wizards in blockbuster NBA trade: report
-
Lens cruise into French Cup quarters, Endrick sends Lyon through
-
No.1 Scheffler excited for Koepka return from LIV Golf
-
Curling quietly kicks off sports programme at 2026 Winter Olympics
-
Undav pokes Stuttgart past Kiel into German Cup semis
-
Germany goalkeeper Ter Stegen to undergo surgery
-
Bezos-led Washington Post announces 'painful' job cuts
-
Iran says US talks are on, as Trump warns supreme leader
-
Gaza health officials say strikes kill 24 after Israel says officer wounded
-
Empress's crown dropped in Louvre heist to be fully restored: museum
-
UK PM says Mandelson 'lied' about Epstein relations
-
Shai to miss NBA All-Star Game with abdominal strain
-
Trump suggests 'softer touch' needed on immigration
-
From 'flop' to Super Bowl favorite: Sam Darnold's second act
-
Man sentenced to life in prison for plotting to kill Trump in 2024
-
Native Americans on high alert over Minneapolis crackdown
-
Dallas deals Davis to Wizards in blockbuster NBA deal: report
Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
V.Dantas--PC